» Articles » PMID: 16548907

Emphysema Detected by Lung Cancer Screening with Low-dose Spiral CT: Prevalence, and Correlation with Smoking Habits and Pulmonary Function in Japanese Male Subjects

Overview
Journal Respirology
Specialty Pulmonary Medicine
Date 2006 Mar 22
PMID 16548907
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Screening with low-dose spiral CT is a promising new tool for early lung cancer detection. A study was undertaken to assess the prevalence of emphysema detected by CT screening, and to assess the correlation between the extent of emphysema and the severity defined according to the recently published Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria.

Methods: After informed consent, CT screening and pulmonary function tests were performed on 615 men between the ages of 40 and 69. Severity of emphysema was assessed visually. Only the pulmonary function data for male subjects were analysed because there were too few female subjects with emphysema.

Results: Emphysema was detected in 30.5% of current smokers, 14.1% of former smokers and 3.0% of non-smokers. In male current smokers, airflow obstruction (FEV(1)/FVC < 0.7) was seen in 18.1% of subjects with mild emphysema, and in 33.3% of subjects with moderate emphysema. FEV(1) values were less than 80% of the predicted normal in 8.5% of subjects with mild emphysema, and 28.6% of subjects with moderate emphysema. The percentage of male subjects with emphysema equivalent to GOLD stage 0 was 90.0% for subjects in their 40s, 82.5% for those in their 50s, and 68.2% for those in their 60s.

Conclusion: A considerable percentage of the subjects with emphysema as detected by CT screening had GOLD stage 0. CT screening assists in detecting early-stage emphysema.

Citing Articles

COVID-19: Mechanisms, risk factors, genetics, non-coding RNAs and neurologic impairments.

Gilyazova I, Timasheva Y, Karunas A, Kazantseva A, Sufianov A, Mashkin A Noncoding RNA Res. 2023; 8(2):240-254.

PMID: 36852336 PMC: 9946734. DOI: 10.1016/j.ncrna.2023.02.007.


The prevalence of comorbidity in the lung cancer screening population: A systematic review and meta-analysis.

Almatrafi A, Thomas O, Callister M, Gabe R, Beeken R, Neal R J Med Screen. 2022; 30(1):3-13.

PMID: 35942779 PMC: 9925896. DOI: 10.1177/09691413221117685.


Impact of Computed Tomography-Quantified Emphysema Score on Clinical Outcome in Patients with COVID-19.

Lim J, Park B, Park J, Choi K, Jung C, Kim Y Int J Gen Med. 2021; 14:3327-3333.

PMID: 34285557 PMC: 8285278. DOI: 10.2147/IJGM.S317295.


Chronic obstructive pulmonary disease prevalence and prediction in a high-risk lung cancer screening population.

Goffin J, Pond G, Puksa S, Tremblay A, Johnston M, Goss G BMC Pulm Med. 2020; 20(1):300.

PMID: 33198781 PMC: 7670711. DOI: 10.1186/s12890-020-01344-y.


Diagnosis and Treatment of Early Chronic Obstructive Lung Disease (COPD).

Choi J, Rhee C J Clin Med. 2020; 9(11).

PMID: 33114502 PMC: 7692717. DOI: 10.3390/jcm9113426.